Holen Sie sich die Stockscreener-App
206.76
0.06%
-0.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$206.89
Offen:
$206.79
24-Stunden-Volumen:
983.65K
Relative Volume:
0.84
Marktkapitalisierung:
$29.99B
Einnahmen:
$5.54B
Nettoeinkommen (Verlust:
$1.52B
KGV:
19.93
EPS:
10.3734
Netto-Cashflow:
$1.74B
1W Leistung:
+0.85%
1M Leistung:
-10.38%
6M Leistung:
-17.79%
1J Leistung:
-14.95%
1-Tages-Spanne:
$203.92
$207.98
1-Wochen-Bereich:
$203.92
$213.53
52-Wochen-Spanne:
$198.64
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
206.76 | 29.99B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
450.06 | 159.39B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
149.43 | 41.17B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
39.52 | 33.42B | 29.14B | 1.07B | 1.52B | 1.1995 |
ALC
Alcon Inc
|
62.56 | 30.51B | 10.40B | 980.00M | 1.61B | 1.9749 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
ResMed Inc stock (AU000000RMD6): Sleep apnea and respiratory care leader posts strong growth outlook - AD HOC NEWS
ResMed (NYSE:RMD) Could Be A Buy For Its Upcoming Dividend - Yahoo Finance
Should you continue to hold Resmed stock in your portfolio? - MSN
ResMed Inc. stock: Earnings beat but shares slip on guidance concerns - AD HOC NEWS
Number of shareholders of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – LSX:935168 - TradingView
ResMed, Inc. Experiences Valuation Adjustment Amid Competitive Pharmaceuticals Sector Landscape - Markets Mojo
Mitsubishi UFJ Asset Management Co. Ltd. Increases Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by Strs Ohio - MarketBeat
ResMed expects FY 2026 gross margin of 62%-63% as it plans $175M+ Q4 buybacks and targets June 1 close for $340M Noctrix deal - MSN
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
[144] RESMED INC SEC Filing - Stock Titan
QRG Capital Management Inc. Has $5.39 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Resmed boosts sleep health portfolio with Noctrix buy - BioWorld News
ResMed Stock Is Down 22% in 2026: Here’s Why Analysts Still Sees $256 Fair Value - TIKR.com
Piper Sandler Maintains ResMed(RMD.US) With Hold Rating, Cuts Target Price to $233 - Moomoo
Swedbank AB Has $265.55 Million Holdings in ResMed Inc. $RMD - MarketBeat
Harel Insurance Investments & Financial Services Ltd. Decreases Stock Holdings in ResMed Inc. $RMD - MarketBeat
Wall Street's insights into key metrics ahead of ResMed (RMD) Q3 earnings - MSN
ResMed, Inc. Hits New 52-Week Low at USD 210.67 - Markets Mojo
Resmed enters merger agreement to acquire Noctrix Health for $340 million - MassDevice
9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time - Investing.com
Resmed integrating AI for sleep apnea treatment - Yahoo Finance
Here's why ResMed (RMD) is a strong growth stock - MSN
Birch Capital Management LLC Reduces Stock Holdings in ResMed Inc. $RMD - MarketBeat
RMD Stock Price, Quote & Chart | RESMED INC (NYSE:RMD) - ChartMill
Stifel Nicolaus Adjusts ResMed Price Target to $235 From $265 - Moomoo
Ord Minnett Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
[Form 3] RESMED INC Initial Statement of Beneficial Ownership - Stock Titan
ResMed (RMD) CFO Brett Sandercock reports direct holding of 83,495 shares - Stock Titan
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed Inc. (RMD) Stock Analysis: Exploring a 31.99% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ResMed (RMD) Is Down 6.7% After Earnings Beat And CFO Transition NewsWhat's Changed - Sahm
ResMed announces CFO succession - MSN
Market Chatter: CSL, Resmed, Cochlear Lead Losses on ASX - Moomoo
ResMed Price Target Cut 13% to A$41.72/Share by Morgans - Moomoo
CSL, Resmed, Cochlear Lead Losses on ASX - marketscreener.com
ResMed Price Target Cut 2% to A$46.50/Share by Macquarie - Moomoo
ResMed Updates CDI Count Amid Routine Share Transfers, Issuances and Buybacks - TipRanks
ResMed: Q3 result 2026 - intelligentinvestor.com.au
ResMed Inc. 2026 Q3ResultsEarnings Call Presentation (NYSE:RMD) 2026-05-03 - Seeking Alpha
ResMed Files March 2026 Quarterly Report Detailing Capital Structure and Compliance Status - TipRanks
ResMed (RMD) Margin Strength At 27.5% Tests Bearish Cost And GLP 1 Narratives - Sahm
ResMed Stock Fell 8% This Week. Here’s What a Strong Earnings Beat Means for the Recovery Case - TIKR.com
Why ResMed (RMD) Narrative Is Shifting As Analysts Reassess Growth And Valuation Assumptions - Yahoo Finance
Pittenger & Anderson Inc. Acquires 5,421 Shares of ResMed Inc. $RMD - MarketBeat
PFA Pension Forsikringsaktieselskab Buys Shares of 188,393 ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Stake Cut by Danske Bank A S - MarketBeat
ResMed Shifts Leadership And Adds Neurology With Noctrix Acquisition - Sahm
ResMed: Stock splutters, but machine is still breathing well - marketscreener.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Immunome (IMNM) and Resmed (RMD) - The Globe and Mail
ResMed Q3 Earnings Call Highlights - Yahoo Finance
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.07%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):